Activity Details

Credit Types:	CME / CE
Credit Amount:	1.0 CME/CE
Release Date:	2018-Mar-26
Expiration Date:	2019-Mar-25
Estimated Time for Completion:	60 minutes
Registration Required:	No
Cost:	Free of charge

Activity Description and Educational Objectives

In this activity, experts in hepatocellular carcinoma (HCC) discuss how immunotherapy and novel targeted approaches can be used to improve outcomes for patients with HCC.

Upon completion of this activity, participants will be able to:

• Describe safety and efficacy data for currently approved and emerging systemic targeted therapies for advanced HCC
• Explain the role of immune checkpoint proteins in tumor biology, the mechanism of action of checkpoint inhibitors, and the rationale for targeting immune checkpoints for the treatment of advanced HCC
• Discuss safety and efficacy data from clinical trials for immune checkpoint inhibitors in advanced HCC including the management of immune-related adverse events
• Select appropriate treatment options, including enrollment in a clinical trial, for patients with advanced HCC by comparing the safety and efficacy of approved versus emerging systemic targeted and immunotherapies

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, hepatologists, interventional radiologists, hepatobilary surgeons, pathologists, radiologists, gastroenterologists, advanced practice oncology clinicians, nurses, and other professionals involved in HCC manangement.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of HCC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 26, 2018 - March 25, 2019
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity during the past 12 months.

Course Director and Moderator

Ghassan Abou-Alfa, MD, MBA
Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant for Agios Pharmaceuticals; Amgen; Aptus Pharmaceuticals, Inc.; ASLAN Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Bayer; Boston Scientific Corporation; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals, Inc.; Celgene Corporation; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; Delcath Systems Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Halozyme, Inc.; Inovio Pharmaceuticals, Inc.; Ipsen; MedImmune; Merck & Co., Inc.; Onxeo; PCI Biotech; sanofi-aventis; Servier; Silenseed; SillaJen Inc; Sirtex; and Yakult Pharmaceutical Industry.
Grant/Research Support from Agios Pharmaceuticals; Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; CASI Pharmaceuticals, Inc.; Celgene Corporation; Exelixis; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Incyte Corporation; Lilly; MabVax Therapeutics Holdings, Inc.; MedImmune; Momenta Pharmaceuticals; Novartis Pharmaceuticals Corporation; and OncoMed Pharmaceuticals. (Research support to Institution)
Ghassan Abou-Alfa, MD, MBA, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including but not limited to cabozantinib, lenvatinib, regorafenib; other targeted agents; immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.

Faculty

Anthony El-Khoueiry, MD
Associate Professor of Clinical Medicine
Medical Director of Clinical Investigations Support Office
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California

Anthony El-Khoueiry, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer HealthCare Pharmaceuticals, Inc. and Bristol-Myers Squibb.
Advisory Board for AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; CytomX Therapeutics; Eisai Inc.; F. Hoffmann-La Roche/Genentech, Inc.; and Novartis Pharmaceuticals Corporation.
Anthony El-Khoueiry, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including but not limited to cabozantinib, lenvatinib, regorafenib; other targeted agents; immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.

R. Kate Kelley, MD
Associate Professor of Clinical Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

R. Kate Kelley, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Adaptimmune; Agios, Inc.; AstraZeneca; Bayer Corporation; Bristol-Myers Squibb Company; Celgene Corporation; Debiopharm Group; Eli Lilly and Company; Exelixis, Inc.; Medimmune; Merck & Co., Inc.; Novartis Corporation; Taiho Pharmaceutical, Co. Ltd.; TARGET PharmaSolutions; and Tekmira Pharmaceuticals. (Research support to Institution)
Other Financial or Material Support from Expert Panel/CME for Medscape and OncLive.
R. Kate Kelley, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including but not limited to cabozantinib, lenvatinib, regorafenib; other targeted agents; immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer

Bobbie Perrin, RN, OCN
Harrington Cancer Center
Amarillo, Texas

Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Marie Becker, PhD
PVI, PeerView Institute for Medical Education

Marie Becker, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour(s).

Providership

This CME/CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported through medical education grants from Bayer HealthCare Pharmaceuticals, Inc., Bristol-Myers Squibb, Eisai Inc., and Exelixis, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/CE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView